References
- Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006;3:47-52
- Torre GL, Gualano MR, Semyonov L et al. Hepatitis C virus infections trends in Italy, 1996–2006. Hepat Mon 2011;11:895-900
- Cornberg M, Razavi HA, Alberti A et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver International 2011;31:30-60
- Ciampichini R, Scalone L, Fagiuoli S, et al. Societal burden in hepatitis C patients: the come study results. Value in Health Conference: 17th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR, 2 June 2012, Washington, DC, USA
- Mennini FS. Il costo dell'epatite C. WEF, 2012. Facoltá di Economia, Universitá di Roma Tor Vergata and Kingston Business School, Kingston University, London, UK
- EASL (European Association for the Study of the Liver). EASL Recommendations on Treatment of Hepatitis C. 2014. http://files.easl.eu/easl-recommendations-on-treatment-of-hepatitis-C.pdf [last accessed 30 January 2015]
- Therapy KnowlEdge HCV di Edge Consulting srl., 2014
- North CS, Hong BA, Adewuyi SA, et al. Hepatitis C treatment and SVR: the gap between clinical trials and real-world treatment aspirations. Gen Hosp Psychiatry 2013;35:122-8
- Falck-Ytter Y, Kale H, Mullen KD, et al. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002;136:288-92
- Belperio PS, Hwang EW, Thomas IC, et al. Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C. Clin Gastroenterol Hepatol 2013;11:1021-7
- Shah N, Pierce T, Kowdley KV. Review of direct-acting antiviral agents for the treatment of chronic hepatitis C. Expert Opin Investig Drugs 2013;22:1107-21
- EMA. Sovaldi Summary of Product Characteristics (SmPC). 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002798/WC500160597.pdf [last accessed 30 January 2015]
- EASL. Clinical practice guidelines: management of hepatitis C virus infection. J Hepatol 2014;60:392-420
- Shepherd J, Jones J, Hartwell D et al. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess 2007;11:1-224
- Hartwell D, Jones J, Baxter L, et al. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Health Technol Assess 2011;15:i-210
- Chen J, Florian J, Carter W, et al. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013;144:1450-5
- Fattore G. Proposta di linee guida per la valutazione economica degli interventi sanitari in Italia. Pharmacoeconomics Ital Res Articles 2009;11:83-93
- Craxi A, Piccinino F, Ciancio A, et al. Real-world outcomes in patients with chronic hepatitis C: primary results of the PROBE study. Eur J Gastroenterol Hepatol 2014;26:388-95
- McLauchlan J. Query of 5000 anonymised patient records performed October 2013. HCV UK Research Database, 2013
- Associazione italiana per lo studio del fegato. 2011. Available at: http://www.webaisf.org/ [last accessed 30 January 2015]
- Bacon B, Dieterich D, Flamm S, et al. Efficacy of sofosbuvir and simeprevir-based regimens for HCV treatment-experienced GT1 patients in a real-life setting; data from the TRIO network. 65th Annual Meeting of the American Association for the Study of Liver Diseases, 7 November 2014, Boston, MA, USA
- EMA. Incivo Summary of Product Characteristics (SmPC). 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002313/WC500115529.pdf [last accessed 30 January 2015]
- EMA. Victrelis Summary of Product Characteristics (SmPC). 2014. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002332/WC500109786.pdf [last accessed 30 January 2015]
- Grishchenko M, Grieve RD, Sweeting MJ, et al. Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice. Int J Technol Assess Health Care 2009;25:171-80
- Istituto nazionale di statistica. 2012. Available at: http://www.istat.it/it/istituto-nazionale-di-statistica [last accessed 30 January 2015]
- Wright M, Grieve R, Roberts J, et al. Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation. Health Technol Assess 2006;10:1-113, iii
- Younossi ZM, Stepanova M, Henry L, et al. Minimal impact of sofosbuvir and ribavirin on health related quality of life in chronic hepatitis C (CH-C). J Hepatol 2014;60:741-7
- National Institute for Health and Clinical Excellence. Telaprevir for the treatment of genotype 1 chronic hepatitis C – NICE technology appraisal guidance 252. 2012. http://www.google.com/url?url=http://www.nice.org.uk/guidance/ta252/resources/guidance-telaprevir-for-the-treatment-of-genotype-1-chronic-hepatitis-c-pdf&rct=j&frm=1&q=&esrc=s&sa=U&ei=gtg0VbGEEJGxogSA8oGoCg&ved=0CBQQFjAA&usg=AFQjCNGNJVJwQ8VpskiuxEmm8Lx9__YHWA [last accessed 30 January 2015]
- National Institute for Health and Clinical Excellence. Boceprevir for the treatment of genotype 1 chronic hepatitis C – NICE technology appraisal guidance 253. 2012. https://www.google.com/url?url=https://www.nice.org.uk/guidance/ta253/resources/guidance-boceprevir-for-the-treatment-of-genotype1-chronic-hepatitisc-pdf&rct=j&frm=1&q=&esrc=s&sa=U&ei=udg0VYXZMoG3ogSS-YCoCQ&ved=0CBQQFjAA&usg=AFQjCNGFzlFb8l_IvkzCpDcKtd-2oAL2IQ [last accessed 30 January 2015]
- Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002;21:271-92
- Gray AM, Rivero-Arias O, Clarke PM. Estimating the association between SF-12 responses and EQ-5D utility values by response mapping. Med Decis Making 2006;26:18-29
- Remunerazione delle prestazioni di assistenza ospedaliera per acuti, assistenza ospedaliera di riabilitazione e di lungodegenza post acuzie e di assistenza specialistica ambulatoriale. Supplemento ordinario alla ‘Gazzetta Ufficiale' n. 23 del 28 gennaio 2013 – Serie generale. DM, 2012. http://www.gazzettaufficiale.it/eli/id/2013/01/28/13A00528/sg
- Petta S, Cabibbo G, Enea M, et al. Cost-effectiveness of sofosbuvir-based triple therapy for untreated patients with genotype 1 chronic hepatitis C. Hepatology 2014;59:1692-705
- Leleu H, Blachier M, Rosa I. Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C. J Viral Hepat 2015;22:376-83
- Deuffic-Burban S, Schwarzinger M, Obach D, et al. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141). J Hepatol 2014;61:7-14
- San MR, Gimeno-Ballester V, Blazquez A, et al. Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C. Gut 2014. pii: gutjnl-2014-307772. doi: 10.1136/gutjnl-2014-307772. [Epub ahead of print]
- Saab S, Gordon SC, Park H, et al. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther 2014;40:657-75
- Lawitz E, Zeuzem S, Nyberg L, et al. Boceprevir (BOC) Combined with Peginterferon alfa-2b/Ribavirin (P/RBV) in Treatment-Naïve Chronic HCV Genotype 1 Patients with Compensated Cirrhosis: Sustained Virologic Response (SVR) and Safety Subanalyses from the Anemia Management Study, Abstract 50. Boston, MA: AASLD, 9–12 November 2012
- McHutchison JG, Lawitz EJ, Shiffman ML, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-93
- Lagging M, Rembeck K, Rauning BM, et al. Retreatment with peg-interferon and ribavirin in patients with chronic hepatitis C virus genotype 2 or 3 infection with prior relapse. Scand J Gastroenterol 2013;48:839-47
- Shoeb D, Rowe IA, Freshwater D, et al. Response to antiviral therapy in patients with genotype 3 chronic hepatitis C: fibrosis but not race encourages relapse. Eur J Gastroenterol Hepatol 2011;23:747-53
- Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65
- Thomson BJ, Kwong G, Ratib S, et al. Response rates to combination therapy for chronic HCV infection in a clinical setting and derivation of probability tables for individual patient management. J Viral Hepat 2008;15:271-8
- Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997;112:463-72